Pharmaguy's Insights Into Drug Industry News
186.0K views | +34 today
Follow
Pharmaguy's Insights Into Drug Industry News
Pharmaguy curates and provides insights into selected drug industry news and issues.
Curated by Pharma Guy
Your new post is loading...
Your new post is loading...
Scooped by Pharma Guy
Scoop.it!

Grading FDA Commissioner Gottlieb & PhRMA's "Go Boldly" Campaign

Grading FDA Commissioner Gottlieb & PhRMA's "Go Boldly" Campaign | Pharmaguy's Insights Into Drug Industry News | Scoop.it

Food and Drug Administration Commissioner Scott Gottlieb earned high marks from [a STAT Plus] survey respondents.

 

One respondent explained why Gottlieb deserved an F: “I see no vision or mission except keep Trump happy. Good luck.”

 

But the vast majority sang his praises.

 

  • “He’s shown an independence from the pharmaceutical industry that I was not expecting and seems dedicated to balancing safety with efficiency.”

 

  • “He’s a moderate! Speeding things along but not foolishly.”

 

  • “Dr. Gottlieb seems interested in getting other agencies to do their jobs. He seems interested in improving competition and drug shortage to the best of FDA’s ability — although these problems are pharma’s to fix — not FDA’s.”

 

Further Reading:

  • “Dr. Scott Gottlieb’s Plan to ‘Get Things Done’ at #FDA is Approved by #Pharma”; http://sco.lt/7iW5TN
  • “Does Pharma Really Want to Abandon the ‘Gold Standard’ of the FDA Approval Process?”; http://sco.lt/74r19d
  • “Pharma Scientists Concerned About Gottlieb’s Industry Ties”; http://sco.lt/8jOq0n

 

The trade group PhRMA has tried to reframe the drug price debate with its “Go Boldly” campaign, paid for by a hike in membership fees. In decidedly lukewarm reviews, more than a third of respondents gave that initiative a modest 2 on a scale of 1 to 5 (with 5 being a rave). Roughly a quarter split between 1 (the worst) and 3 (meh), though one respondent noted that “featuring industry scientists was a great choice, from a PR standpoint.”

 

Among the other comments:

 

  • “All the ‘bold’ in the world doesn’t matter when people can’t afford treatments.”

 

  • “The ads are good. … People like pharma for the drugs it produces. Its R&D is not what galls people. It’s pricing and business practices.”

 

  • “There’s a ‘Go Boldly’ campaign?”

 

Further Reading:

  • “He Boldly Stars in @PhRMA's Multi-Million $ Ad Campaign, But Has No Money to Pay His Rent”; http://sco.lt/5BIFgP
more...
No comment yet.
Scooped by Pharma Guy
Scoop.it!

Biopharma execs give Scott Gottlieb’s nomination for FDA commish (almost) a standing O in Endpoints poll

Biopharma execs give Scott Gottlieb’s nomination for FDA commish (almost) a standing O in Endpoints poll | Pharmaguy's Insights Into Drug Industry News | Scoop.it

A big majority of biopharma executives overall are clearly enthusiastic about President Trump’s decision to nominate Scott Gottlieb as the next FDA commissioner.

In our snap poll over the weekend Gottlieb picked up 87% support among the 580 qualified subscribers who voted on the decision, with 504 approving the choice against 76 who largely hated it.

 

[Public Citizen, however, said “[Gottlieb] Has Extensive Industry Ties and Dangerous Deregulatory Ideas”.]

 

more...
No comment yet.